US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Notice of extraordinary general meeting in Biosergen AB

The shareholders of Biosergen AB, Reg. No. 559304-1295 (the "Company" or “Biosergen”), are invited to attend the extraordinary general meeting to be held on 6 August 2026 at 16:00 at BAHR Advokatbyrå at Birger Jarlsgatan 16,  Stockholm. Registration for the meeting begins at 15:30.Right to participate Shareholders wishing to participate in the extraordinary general meeting must: · be listed in the Company's share register kept by Euroclear Sweden AB as of 29 July 2026; and · have given a notice of their intent to participate to the Company no later than on 31 July 2026. The

Bulletin from the annual general meeting of Biosergen AB

Biosergen AB reg. no. 559304-1295 ("Biosergen" or the "Company") held its annual general meeting today, 30 June 2026, at BAHR Advokatbyrå, Birger Jarlsgatan 16, 114 34 Stockholm, where the below resolutions were adopted. All resolutions were adopted in accordance with the proposals presented, which are described in detail in the notice convening the annual general meeting, available on the Company's website, www.biosergen.net.Resolution on adoption of the income statement and balance sheet and the consolidated income statement and consolidated balance sheet, and appropriation of profits

Statement from the Board of Directors of Biosergen regarding the merger with Flerie

This statement is made by the Board of Directors of Biosergen AB (the "Company" or "Biosergen") pursuant to Section II.19 of the Swedish takeover rules for certain trading platforms (the "Takeover Rules"), due to the proposed merger between Biosergen and Flerie AB (”Flerie”). The Board of Directors of Biosergen (the "Board") has resolved to recommend the shareholders of Biosergen to vote in favour of the merger.Background The Boards of Directors of Biosergen and Flerie (together the "Companies") today jointly announced that the Board and the Board of Directors of Flerie have adopted a

The Board of Directors of Biosergen has resolved on a rights issue of shares of approximately SEK 40 million in connection with the merger with Flerie

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, WHETHER DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION WOULD BE PROHIBITED. The Board of Directors of Biosergen AB (“Biosergen” or the “Company”) has today, on 26 June 2026, conditional upon the subsequent approval of the Extraordinary General Meeting, resolved on a rights issue of shares (the “Rights Issue”). The subscription price has been set at SEK 0.50 per share. The Company has

Flerie and Biosergen have agreed on a merger plan – Flerie’s first new investment since its listing on Nasdaq Stockholm

THIS ANNOUNCEMENT SHOULD NOT BE DISTRIBUTED, WHETHER DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, JAPAN, NEW ZEALAND, SOUTH AFRICA OR THE UNITED STATES OF AMERICA. THIS ANNOUNCEMENT SHOULD ALSO NOT BE DISTRIBUTED IN OR INTO ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION REQUIRES ANY OTHER DOCUMENTATION, REGISTRATION, OR MEASURES BEYOND WHAT IS GOVERNED BY SWEDISH LAW. Today, on 26 June 2026, Flerie AB (publ) (”Flerie”) and Biosergen AB (“Biosergen”) (together the ”Companies”) jointly announce that the Board of Directors of Flerie and the Board of Directors of Biosergen have

Biosergen Publishes 2025 Annual Report

June 26, 2026: Biosergen AB (“Biosergen” or the “Company”) hereby announces that the 2025 annual report is available on the company website www.biosergen.net   For further information about Biosergen, please contact:Tine Kold Olesen, CEO Telephone: +45 3135 5707E-mail: tine.olesen@biosergen.net Mark Beveridge, CFO Telephone: +46 76 805 8288E-mail: mark.beveridge@biosergen.net The Company's Certified Adviser is Carnegie Investment Bank AB (publ).

Notice of annual general meeting in Biosergen AB

The shareholders of Biosergen AB, Reg. No. 559304-1295, (the "Company") are invited to attend the annual general meeting to be held on June 30, 2026, at 14:00 at BAHR Advokatbyrå at Birger Jarlsgatan 16, SE-114 34, Stockholm. Registration for the meeting begins at 13:30.Right to participate Shareholders wishing to participate in the annual general meeting must: · be listed in the Company's share register kept by Euroclear Sweden AB as of June 22, 2026; and · have given a notice of their intent to participate to the Company no later than on June 24, 2026. The notification should

Biosergen Pauses Development of BSG005

PRESS RELEASESTOCKHOLM, APRIL 4th 2026Against the backdrop of a continued challenging financing environment, the Board of Directors of Biosergen AB (OMX: BIOSGN) has today resolved to pause the development of BSG005. As disclosed in previous quarterly reports, the manufacture of new drug substance has resulted in delays in the development of Biosergen’s product candidate BSG005. The year-end report published on 10 February 2026 stated that the company’s financial position needs to be strengthened in order to ensure continued operations. Despite extensive efforts, the company has not been

Biosergen publishes interim report for the fourth quarter 2025

February 10, 2026: Biosergen AB (“Biosergen” or the “Company”) hereby publishes the interim report for the fourth quarter 2025. The interim report is available as an attached document and on the company website (www.biosergen.net) Advancing BSG005 Toward Cohort 3 and Strengthening Key Program Foundations Progress in GMP Manufacturing of BSG005 and Successful Pre-IND meeting with good guidance from FDA“During the fourth quarter, our primary operational focus remained on preparing the BSG005 program for its next phase of advancement. In particular finalization of drug supply to ensure

Determination of Record Date for Reverse Share Split in Biosergen

STOCKHOLM, November 20, 2025. At the Annual General Meeting of Biosergen AB (“Biosergen” or the “Company”) on June 11, 2025, a resolution was passed on a reverse split of shares, whereby one hundred (100) existing shares are reversed into one (1) share (reversal ratio 1:100). The Board of Directors was further authorized to determine the record date for the reverse split. Biosergen’s Board of Directors has today resolved that the record date for the reverse split shall be December 2, 2025.Through the reverse share split, the total number of shares in the Company will decrease from 234,823,

Biosergen publishes interim report for the third quarter 2025

November 19, 2024: Biosergen AB (“Biosergen” or the “Company”) hereby publishes the interim report for the third quarter 2025. The interim report is available as an attached document and on the company website (www.biosergen.net)  Advancing BSG005 Toward Cohort 3 and Key Appointments  Progress in GMP Manufacturing of BSG005 and U.S. IND Submission Preparations“During the third quarter of 2025, we focused on preparing for the next phase of BSG005’s development. The manufacturing of a new GMP-compliant batch is progressing according to plan and will support both Cohort 3 and our

Biosergen’s Nomination Committee appointed

STOCKHOLM, October 28th, 2025 – In accordance with the resolution of the Annual General Meeting on June 11th, 2025, the Chairman of the Board has contacted the company’s two largest shareholders or group of shareholders in terms of votes to form a Nomination Committee. These shareholders have been invited to appoint one representative each who, together with the Chairman of the Board, will comprise the Nomination Committee.Biosergen’s Nomination Committee ahead of the Annual General Meeting for the fiscal year January – December 2025 comprises:   • Eric Strandqvist, appointed by

Biosergen publishes its interim report for the second quarter 2025

Wednesday August 20, 2024: Biosergen AB (“Biosergen” or the “Company”) hereby publishes the interim report for the second quarter 2025. The interim report is available as an attached document and on the company website (www.biosergen.net)Advancing BSG005 Toward Cohort 3 and Key Appointments“During the second quarter of 2025, we made solid progress on several key fronts. Manufacturing a new GMP-compliant batch of BSG005 is underway to support the start of Cohort 3 later this year and the phase 2/3 program. At the same time, we continued our regulatory discussions in India and advanced

Biosergen Appoints Mark Beveridge as Chief Financial Officer

Stockholm, Sweden – July 24, 2025 – Biosergen AB (“Biosergen” or the “Company”), a clinical-stage biotechnology company developing therapies for life-threatening fungal infections, today announces the appointment of Mark Beveridge as its new Chief Financial Officer. Mark succeeds Niels Laursen, who will remain with the Company during a transition period to ensure continuity and support a smooth handover.“We are very pleased to welcome Mark to Biosergen’s leadership team,” said Tine K. Olesen, CEO of Biosergen. “He brings extensive financial expertise and a proven track record in supporting

Bulletin from the annual general meeting in Biosergen AB (publ)

At the annual general meeting in Biosergen AB (publ) (the “Company”) held today, June 11, 2025, the below resolutions were adopted. All resolutions were adopted in accordance with the presented proposals, which are described in detail in the notice to the annual general meeting available on the Company’s website, www.biosergen.net.Resolution on adoption of accounts and allocation of the Company’s profits The annual general meeting resolved to adopt the profit and loss statement and balance sheet as well as the consolidated profit and loss statement and consolidated balance sheet. The

Biosergen publishes interim report for the first quarter 2025

May 21, 2025: Biosergen AB (“Biosergen” or the “Company”) hereby publishes the interim report for first quarter 2025. The interim report is available as an attached document and on the company website (www.biosergen.net)BSG005 Demonstrates Therapeutic Effect in High-Risk Patients: Cohort 2 Completed2025 will be the year we focus on expanding the clinical path for BSG005 beyond India—by preparing for FDA pre-IND meeting and establishing a future-proof production setup for BSG005—while also progressing toward Phase 2 planning in India. These activities are already in motion, driven by the

Biosergen Nomination Committee Proposes New Board Member with an Extensive Tracking Record in the Development, Commercialization and Out-Licensing of Anti-Infectives

Stockholm, Sweden – May 9, 2025 – Biosergen AB (“Biosergen” or the “Company”), a clinical-stage biotechnology company developing therapies for life-threatening fungal infections, today announces  the proposal of electing Dr. Marco Taglietti, M.D., as a new member of the Board of Directors ahead of the upcoming Annual General Meeting.The proposal is made in light of the Company’s continued promising clinical development of its antifungal drug candidate, BSG005, which is currently being investigated in a proof-of-concept trial as a rescue therapy for patients who have failed previous standard-

Notice of annual general meeting in Biosergen AB

The shareholders of Biosergen AB, Reg. No. 559304-1295, (the “Company”) are invited to attend the annual general meeting to be held on Wednesday June 11, 2025, at Fogdevreten 2A, SE-171 65 Solna, at 11:00.Right to participate and notice of participation Shareholders wishing to participate in the annual general meeting must: · be listed in the Company’s share register kept by Euroclear Sweden AB as of Monday June 2, 2025; and · have given a notice of their intent to participate to the Company no later than on Wednesday June 4, 2025 by post to Advokatfirman Hammarskiöld & Co, Att:

BioStock: Biosergen takes aim at climate-driven fungal infections

Research shows that climate change is driving the rapid spread of Aspergillus, a mold causing deadly infections. Rising temperatures, extreme weather, and elevated CO2 levels create ideal conditions for fungal proliferation, threatening vulnerable populations worldwide. To address this, Biosergen is developing BSG005, a novel antifungal with potent, broad-spectrum efficacy and a strong safety profile.Read the article at biostock.se: https://www.biostock.se/en/2025/05/biosergen-takes-aim-at-climate-driven-fungal-infections/ This is a press release from BioStock - Connecting Innovation &

BioStock: Biosergen’s CEO on the latest advancements

As fungal infections continue to be recognized as a growing global health problem, Biosergen is sharpening its focus. The company’s recently published annual report highlights the clinical progress made in 2024 and its priorities in addressing an area with significant unmet medical needs. We contacted CEO Tine Olesen for a comment.Read the interview at biostock.se: https://www.biostock.se/en/2025/05/biosergens-ceo-on-the-latest-advancements/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

BioStock: Biosergen scales up for future wins

Biosergen is charging into 2025 with momentum, building on a transformative 2024 that showcased the life-saving potential of its antifungal drug candidate, BSG005. As the biotech company continues its mission to combat the global crisis of life-threatening fungal infections, it is focused on key strategic priorities for the year ahead expanding clinical trials, accelerating development, and strengthening its global presence.Read the article at biostock.se: https://www.biostock.se/en/2025/03/biosergen-scales-up-for-future-wins/This is a press release from BioStock - Connecting

Biosergen publishes interim report for fourth quarter 2024

March 5, 2025: Biosergen AB (“Biosergen” or the “Company”) hereby publishes the interim report for fourth quarter 2024. The interim report is available as an attached document and on the company website (www.biosergen.net2025: STRENGTHENING BIOSERGEN’S POSITION FOR GLOBAL TRIALS2025 will be the year we expect to initiate substantial discussions with the U.S. FDA on securing an Investigational New Drug (IND) application for BSG005—an essential step toward conducting clinical trials in the U.S. We plan to enter these discussions with strong clinical data from our ongoing trial in India and

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe